Guest guest Posted December 28, 2010 Report Posted December 28, 2010 Some of us may be unaware that the standards for approval are based on Congressional law, not the arbitrary wishes of FDA ... That is, the results of clinical testing must show clear evidence of meaningful clinical benefit - addresses an unmet need, or is an improvement over the standard of care. .... Usually, unless you select for patients with refractory disease, this requires a test against an active control. So I expect that sponsors choose to test XYZ with Rituxan / etc in early phase studies to see if there is a signal there that it will beat Rituxan alone in a head-to-head study. This is okay IMO only if Rituxan (or whatever the chosen control..) is the standard of care for the clinical circumstance of the eligible participants. If not, you get accrual problems, or worse - you get misinformed participants delaying more appropriate therapy. The companies (for-profit entities PERIOD) of course want the standards lowered. But that would mean an increase of inadequately studied drugs on the market - and more confusion about what to use and when, increasing risk to patients - and if this is okay for one drug, it's okay for all drugs. Without standards for marketing approval we would have medical practice based on sales pitch and theory-based opinions. A return to the dark ages. Karl Drug companies want to have it all; the compliant patients, the cheap process, excellent results. I understand that the FDA is one major culprit, as Dr. Keating has written, they want more and more data every year, ratcheting up the cost to ever higher and higher levels. > > But the drug companies share a lot of the blame as well. > > One thing interests the drug companies. The bottom line. That's it. > Quote
Guest guest Posted December 28, 2010 Report Posted December 28, 2010 Sorry my CLL friends, As an advocate trying to get us a better system, I disagree with parts of this previous thought process. Drug companies are our friends and in my opinion they should be rewarded heavily financially for their efforts. Don't we all expect to come home with some financial benefit at the end of the day? Why should a drug company be any different. Such financial reward will only motivate more research and more successful drug strategies in the future. It is an absolute shame that it takes so much money to get a drug into a trial and once proven successful in the first clinical trial, years go by before widespread acceptance of these lifesaving strategies........all the while we watch our fellow CLLers die in the process. It is much worse for other more acute illnesses. IMO our system is in the DARK AGES now and Thank GOD there are those trying to improve it. For those interested, check out the Abigail foundation. They are in process of making successful phase I drugs instantly available to near death patients who can benefit from the new drug. This includes us and they deserve our support. Givepatientsafightnigchance.com is trying to allow patients at life's end the ability to dive deep into developing science. Currently, it is impossible due to regulation. I know they need people passionate to the cause in their organization. Our system Karl is designed to protect and it is beneficial that you choose to defend that part of it. However, using the words dark ages when so much can be done and needs to be done to streamline the process is truly unfortunate. IMO dark ages describes the current process that is simply more in line with protection against the snake oil salesmanship of the late 1800s than the current pace of new therapies, science, and strategies being developed in legitimate science centers. Agree to disagree. May we all enjoy a great 2011. Leo Quote
Guest guest Posted December 29, 2010 Report Posted December 29, 2010 Hi Leo, Sorry if my prior post confused. Just to clarify. I agree that financial incentives are essential to drive innovation. Patent law is all about making the venture attractive. That drug development is profit-driven doesn't make it an evil activity, and there are many caring people who work in drug companies I'm certain. But company behavior is machine-like, I think. There mission being to maximize profits for shareholders within the law. But independent review and standards for approval (the requirement that you prove it provides clinical benefit) are also vital to protect patients from ineffective drugs, and vital in order to provide a foundation for additional progress. That said, What is a fair test? .. what is an appropriate level of evidence for a given drug for a specific indication is a work in progress - it can depend a lot on what's available already as therapy, the natural history of the disease including its variability. This is an area I am very keen on - particularly as it relates to feasibility -- will patients participate in the study ... does it make sense as a treatment decision, but also, can the study provide a meaningful answer to a clinical question. Both have to be satisfied for a study to be ethical. Regarding standards, the law doesn't say how you must do it, only that it meets the test: clear evidence of clinical benefit using aprpoved scientific methods. There are plenty of examples of single-arm studies used to successfully win marketing approval, for example - but in many cases where the improvement in activity of a drug is accompanied by greater toxicity, it's easy to get the assessment wrong without a control. (And often we only learn half of the story from media reports - fed to the media by the company sponsoring the rejected drug.) If the independent review system was not fair, why do so many companies continue to participate in it (1,300 trials recruiting for lymphoma/cll today)? Would not the drug companies howl if the system was rigged - was set up as an obstacle for the sake of putting up an obstacle? It's not a perfect review system by any means, and we must be willing to challenge decisions that we consider unfair (assuming we have all the facts), but on the whole I think it has considerable integrity, and is recognized as more efficient than regulatory systems elsewhere in the world. Karl Quote
Guest guest Posted January 1, 2011 Report Posted January 1, 2011 The problem is much more complicated than this. The FDA approvals are based primarily on not just benefit. The two criteria used are: 1)greater benefit than the currently approved therapies (requires head to head comparisons) 2)unmet medical need (nothing approved to compare with) The FDA has suggested that it will not allow any drugs to be further approved for CLL using the unmet medical need criteria. This is how alemtuzumab and ofatumumab have gained approval. Thus, a trial of drug X in patients who have disease that is refractory to fludarabine, bendamustine, alemtuzumab, and ofatumumab will not lead to approval. Even if this agent (like PCI-32765 or CAL-101) has a 90% rate of clinical benefit / response. Likewise, for some very unexplicable reason, the FDA will not allow multiple drugs to be approved at the same indication. There are 25 different anti-hypertensives and 10 different cholesterol lowering agents. They did not have to prove themselves better than the currently available therapies. Just that they were efficacious. Why not the same thing for oncology drugs? Why can we not just show CAL-101 benefit patients and get it approved? Additionally, the FDA will not approve an agent that is equally effective, but less toxic over the current standard of care. This would require a large study secondary to statistical reasons, but once done, would be a much easier means to approve these new agents. These are just two of the glaring issues where the FDA does not function in a manner that is in patients' best interests. People have been complaining or criticizing the pharmaceutical companies, physicians, etc., but all anyone wants is to get excellent agents to the market as quickly and safely as possible. A less burdensome system would also encourage more novel drug development. It could be a simple as once a drug shows efficacy and safety, that there be programs to allow physicians to use these agents in all patients while closely monitoring further data on safey and efficacy. Would it not be great if anyone who needed CAL-101 or PCI-32765 could get it from their local oncologist? I think this is a good opportunity to build a grassroots effort to change the way the FDA makes these decisions. Let us propose starting a campaign to address these inadequacies in drug development. This is something that CIG is very well situated to spearhead. Let me know your thoughts! Rick Furman, MD > > Some of us may be unaware that the standards for approval are based on Congressional law, not the arbitrary wishes of FDA ... That is, the results of clinical testing must show clear evidence of meaningful clinical benefit - addresses an unmet need, or is an improvement over the standard of care. > > ... Usually, unless you select for patients with refractory disease, this requires a test against an active control. So I expect that sponsors choose to test XYZ with Rituxan / etc in early phase studies to see if there is a signal there that it will beat Rituxan alone in a head-to-head study. This is okay IMO only if Rituxan (or whatever the chosen control..) is the standard of care for the clinical circumstance of the eligible participants. If not, you get accrual problems, or worse - you get misinformed participants delaying more appropriate therapy. > > The companies (for-profit entities PERIOD) of course want the standards lowered. But that would mean an increase of inadequately studied drugs on the market - and more confusion about what to use and when, increasing risk to patients - and if this is okay for one drug, it's okay for all drugs. Without standards for marketing approval we would have medical practice based on sales pitch and theory-based opinions. A return to the dark ages. > > Karl > > > Drug companies want to have it all; the compliant patients, the cheap process, excellent results. I understand that the FDA is one major culprit, as Dr. Keating has written, they want more and more data every year, ratcheting up the cost to ever higher and higher levels. > > > > But the drug companies share a lot of the blame as well. > > > > One thing interests the drug companies. The bottom line. That's it. > > > Quote
Guest guest Posted January 1, 2011 Report Posted January 1, 2011 Dr Furman, If I am understanding you correctly, you are saying that the current batch of novel agents being tested in clinical trials such as Cal- 101 and similar drugs may not even come to market because of these ridiculous FDA rules? This is scary and upsetting. I had assumed that because these drugs were looking promising in the clinical trials and if the studies cont. to go well, we would have a new batch of drugs sometime in the future. What you are saying is that this may not be the case? What is wrong with this gov agency that is supposed to be on our side? R Adks NY and AZ Quote
Guest guest Posted January 1, 2011 Report Posted January 1, 2011 Dear Dr. Furman, That the FDA would exclude certain life threatening indications from the accelerated approval path is very surprising to me. Can you can get this communication in writing? Please feel free to call on me to help with such discussions, which should take place in the public domain - which can only help to establish policy that is in the best interest of patients. You might ask for a meeting that includes patient representatives - and specifically request that I attend. The urgent need for effective low toxic therapies for CLL is self evident, and I expect that even a single arm study could readily demonstrate clinical benefit for agents with true value - sufficient to meet current standards for even full approval. My undertanding is that precedence is an important issue in the review of drugs so you may want to review the following publication by FDA on drugs that have won accelerated and full approval for different cancers using non-survival endpoints, many by single arm studies http://www.lymphomation.org/endpoints.pdf Sincere thanks for all that you do. All the best, Karl > > > > Some of us may be unaware that the standards for approval are based on Congressional law, not the arbitrary wishes of FDA ... That is, the results of clinical testing must show clear evidence of meaningful clinical benefit - addresses an unmet need, or is an improvement over the standard of care. > > > > ... Usually, unless you select for patients with refractory disease, this requires a test against an active control. So I expect that sponsors choose to test XYZ with Rituxan / etc in early phase studies to see if there is a signal there that it will beat Rituxan alone in a head-to-head study. This is okay IMO only if Rituxan (or whatever the chosen control..) is the standard of care for the clinical circumstance of the eligible participants. If not, you get accrual problems, or worse - you get misinformed participants delaying more appropriate therapy. > > > > The companies (for-profit entities PERIOD) of course want the standards lowered. But that would mean an increase of inadequately studied drugs on the market - and more confusion about what to use and when, increasing risk to patients - and if this is okay for one drug, it's okay for all drugs. Without standards for marketing approval we would have medical practice based on sales pitch and theory-based opinions. A return to the dark ages. > > > > Karl > > > > > > Drug companies want to have it all; the compliant patients, the cheap process, excellent results. I understand that the FDA is one major culprit, as Dr. Keating has written, they want more and more data every year, ratcheting up the cost to ever higher and higher levels. > > > > > > But the drug companies share a lot of the blame as well. > > > > > > One thing interests the drug companies. The bottom line. That's it. > > > > > > Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.